

S2 Table. Baseline characteristics of NSCLC patients with radiological N1 disease (n=515)

Variable	Total (n=515)	No endosonography (n=200)	Endosonography first (n=315)	p-value
Age (yr)	65.3±9.6	65.3±8.7	65.2±10.1	0.973
Male sex	384 (74.6)	150 (75.0)	234 (74.3)	0.856
BMI (kg/m ²)	24.0±2.9	23.9±2.8	24.1±3.0	0.602
Smoking status				0.839
Never	139 (27.0)	54 (27.0)	85 (27.0)	
Ex-smoker	192 (37.3)	77 (38.5)	115 (36.5)	
Current	184 (35.7)	69 (34.5)	115 (36.5)	
Pack-years	39 (25-50)	40 (25-60)	35 (22-50)	0.007
Underlying pulmonary disease ^{a)}	254 (49.3)	104 (52.0)	150 (47.6)	0.333
History of pulmonary TB	57 (11.1)	20 (10.0)	37 (11.7)	0.538
NTM/Bronchiectasis	11 (2.1)	3 (1.5)	8 (2.5)	0.541
COPD/asthma	208 (40.4)	91 (45.5)	117 (37.1)	0.066
Interstitial lung disease	22 (4.3)	7 (3.5)	15 (4.8)	0.490
Extra-pulmonary comorbidity ^{a)}	147 (28.5)	39 (19.5)	108 (34.3)	<0.001
DM	92 (17.9)	25 (12.5)	67 (21.3)	0.011
Chronic renal disease	10 (1.9)	4 (2.0)	6 (1.9)	>0.999
Chronic heart disease	49 (9.5)	18 (9.0)	31 (9.8)	0.751
Cerebrovascular disease	28 (5.4)	7 (3.5)	21 (6.7)	0.122
Previous history of other cancer ^{b)}	52 (10.1)	21 (10.5)	31 (9.8)	0.809
Pulmonary function test				
FVC (mL) (n=511)	3.55±0.82	3.53±0.77	3.56±0.86	0.701
FVC, predicted % (n=511)	89.4±13.6	89.7±12.8	89.2±14.0	0.640
FEV ₁ (mL) (n=511)	2.49±0.65	2.45±0.61	2.51±0.67	0.294
FEV ₁ , predicted % (n=511)	85.7±16.9	85.5±17.1	85.9±16.7	0.772
FEV ₁ /FVC (%) (n=511)	70.4±10.0	69.8±10.5	70.8±9.6	0.249
DLco (%) (n=507)	82.8±17.7	82.8±17.1	82.8±18.1	0.957
Tumor diameter in CT (mm)	39.1±17.1	38.6±16.4	39.4±17.6	0.761
Radiological T stage ^{c)}				0.147
T1a	1 (0.2)	0 (0.0)	1 (0.3)	
T1b	44 (8.5)	14 (7.0)	30 (9.5)	
T1c	98 (19.0)	46 (23.0)	52 (16.5)	
T2a	118 (22.9)	49 (24.5)	69 (21.9)	
T2b	96 (18.6)	38 (18.4)	58 (19.0)	
T3	114 (22.1)	43 (21.5)	71 (22.5)	
T4	44 (8.5)	10 (5.0)	34 (10.8)	
Synchronous lung cancer, yes	15 (2.9)	5 (2.5)	10 (3.2)	0.657
Histologic type				0.012
Adenocarcinoma	273 (53.0)	91 (45.5)	182 (57.8)	
Squamous cell carcinoma	217 (42.1)	95 (47.5)	122 (38.7)	
Others ^{d)}	25 (4.9)	14 (7.0)	11 (3.5)	
Spatial location				0.083
Peripheral	256 (49.7)	109 (54.5)	147 (46.7)	
Central location	259 (50.3)	91 (45.5)	168 (53.3)	
Tumor attenuation				0.758
Part-solid	41 (8.0)	15 (7.5)	26 (8.3)	
Solid	474 (92.0)	185 (92.5)	289 (91.8)	

<i>EGFR</i> mutation ^{e)}	118/456 (25.9)	35/162 (21.6)	83/294 (28.2)	0.122
Deletion in Exon 19	58/456 (12.7)	20/162 (12.3)	38/294 (12.9)	0.840
L858R	48/456 (10.5)	11/162 (6.8)	37/294 (12.6)	0.051
Others	12/456 (2.7)	4/162 (2.5)	8/294 (2.7)	0.827
<i>ALK</i> mutation ^{f)}	19/460 (4.1)	7/166 (4.2)	12/294 (4.1)	0.944

Values are presented as number (%) or the mean±standard deviation or median (interquartile range). ALK, anaplastic lymphoma kinase; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CT, computed tomography; DLco, diffusing capacity for carbon monoxide; DM, diabetes mellitus; EGFR, epidermal growth factor receptor; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; NSCLC, non–small cell lung cancer; NTM, non-tuberculous mycobacteria; TB, tuberculosis. ^{a)}Patients could have more than one comorbidity, ^{b)}Patients with active malignancies of other organs at the time of lung cancer diagnosis were excluded. All previous cancer history patients were treated by local treatment, and then follow-up with no evidence of cancer recurrence. Stomach cancer (n=18), colon cancer (n=10), prostate cancer (n=6), thyroid cancer (n=5), hepatic cancer (n=3), bladder cancer (n=2), endometrial cancer (n=2), oral cavity cancer (n=2), skin cancer (n=2), cervical cancer (n=1), esophageal cancer (n=1), and renal cancer (n=1), ^{c)}In the case of synchronous lung cancer, the T category of the main lesion were indicated, ^{d)}Large cell neuroendocrine carcinoma (n=17), pleomorphic carcinoma (n=4), adenosquamous carcinoma (n=2), and poorly differentiated carcinoma (n=2), ^{e)}There were a total of 38 subjects in the No endosonography group and a total of 21 subjects in the Endosonography first group who did not undergo EGFR mutation testing. The "others" mutations included L861Q (exon 21), G719X (exon 18), T790M (exon 20), exon 20 insertion, and S768I (exon 20), ^{f)}There were a total of 35 subjects in the No endosonography group and a total of 21 subjects in the Endosonography first group who did not undergo *ALK* mutation testing.